Investor Presentaiton

12 Investor presentation Full year 2022 R&D milestones Diabetes care Obesity care Rare disease Project Insulin Icodec Oral semaglutide (25/50mg) FDC semaglutide/GIP OW Cagrisema T2D Oral GLP-1/GIP STEP HFPEF Semaglutide sc. (7.2 mg) Oral semaglutide (50 mg) PYY 1875 SELECT CVOT Oral Amycretin Sogroya® (Somapacitan) Concizumab Other serious chronic diseases Ziltivekimab (HFPEF) H1 2023 EU/US/CN submission Phase 3 results Phase 2 results Phase 4 results ✓ Phase 3b initation Phase 3 results Phase 1/2 results EU/US/JP decision (GHD) EU submission (HAWI/HBWI) US/JP decision(HAWI/HBWI) Phase 3b initiation Novo NordiskⓇ Regulatory milestones¹ Clinical milestones¹ H2 2023 Phase 3a initiation Phase 1 results Phase 3b results Phase 1 results 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement HA/BWI: Haemophilia A/B with inhibitors; FDC: Fixed dose combination, OW: once weekly; T2D: Type 2 Diabetes Mellitus; US: United States; EU: European Union; JP: Japan, CVOT: Cardiovascular Outcomes Trial; GHD: Growth Hormone Deficiency; HFPEF: Heart failure with preserved ejection fraction; GLP-1: Glucagon Like Peptide 1; GIP: Gastric inhibitory polypeptide

View entire presentation